Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

JNJ-6617

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

J&J

Drug class:

MLL1 inhibitor

‹

›

NPM1 mutation	Leukemia	NPM1 mutation	Leukemia	JNJ-6617 Sensitive: C3 – Early Trials JNJ-6617 Sensitive : C3	JNJ-6617 Sensitive: C3 – Early Trials JNJ-6617 Sensitive : C3
KMT2A mutation	Leukemia	KMT2A mutation	Leukemia	JNJ-6617 Sensitive: C3 – Early Trials JNJ-6617 Sensitive : C3	JNJ-6617 Sensitive: C3 – Early Trials JNJ-6617 Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	venetoclax + JNJ-6617 Sensitive: D – Preclinical venetoclax + JNJ-6617 Sensitive : D	venetoclax + JNJ-6617 Sensitive: D – Preclinical venetoclax + JNJ-6617 Sensitive : D
KMT2A mutation	Acute Myelogenous Leukemia	KMT2A mutation	Acute Myelogenous Leukemia	venetoclax + JNJ-6617 Sensitive: D – Preclinical venetoclax + JNJ-6617 Sensitive : D	venetoclax + JNJ-6617 Sensitive: D – Preclinical venetoclax + JNJ-6617 Sensitive : D